Christopher H van Dyck
Overview
Explore the profile of Christopher H van Dyck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
135
Citations
7515
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sankhe K, Tumati S, Perin J, Rivet L, Vieira D, Rosenberg P, et al.
Int Psychogeriatr
. 2025 Mar;
37(2):100012.
PMID: 40086910
Background: Previous trials have shown improvements in both apathy and cognition with methylphenidate (MPH). Objectives: To assess whether changes in apathy correlated with changes in cognition in the Apathy in...
2.
Bateman R, Li Y, McDade E, Llibre-Guerra J, Clifford D, Atri A, et al.
medRxiv
. 2025 Feb;
PMID: 39974075
Background: Amyloid-plaque removal by monoclonal antibody therapies slows clinical progression in symptomatic Alzheimer's disease; however, the potential for delaying the onset of clinical symptoms in asymptomatic people is unknown. The...
3.
Wang L, Hu W, Dong F, Sheng C, Wu J, Han Y, et al.
Geroscience
. 2025 Jan;
PMID: 39888585
Brain network dynamics have been extensively explored in patients with subjective cognitive decline (SCD). However, these studies are susceptible to individual differences, scanning parameters, and other confounding factors. Therefore, how...
4.
Salardini E, ODell R, Tchorz E, Nabulsi N, Huang Y, Carson R, et al.
bioRxiv
. 2024 Oct;
PMID: 39386453
Background: The pathological effects of amyloid β oligomers (Aβo) may be mediated through the metabotropic glutamate receptor subtype 5 (mGluR5), leading to synaptic loss in Alzheimer's disease (AD). Positron emission...
5.
Miller A, Sharp E, Wang S, Zhao Y, Mecca A, van Dyck C, et al.
Alzheimers Dement
. 2024 Sep;
20(11):7847-7858.
PMID: 39324520
Introduction: Hearing loss is identified as one of the largest modifiable risk factors for cognitive impairment and dementia. Studies evaluating this relationship have yielded mixed results. Methods: We investigated the...
6.
Young J, ODell R, Naganawa M, Toyonaga T, Chen M, Nabulsi N, et al.
J Nucl Med
. 2024 Sep;
65(11):1782-1785.
PMID: 39299782
Simplified methods of acquisition and quantification would facilitate the use of synaptic density imaging in multicenter and longitudinal studies of Alzheimer disease (AD). We validated a simplified tissue-to-reference ratio method...
7.
Tumati S, Herrmann N, Perin J, Rosenberg P, Lerner A, Mintzer J, et al.
Int Psychogeriatr
. 2024 Sep;
36(12):1232-1244.
PMID: 39297292
Objectives: Among participants with Alzheimer's disease (AD) we estimated the minimal clinically important difference (MCID) in apathy symptom severity on three scales. Design: Retrospective anchor- and distribution-based analyses of change...
8.
Lizama B, Williams C, North H, Pandey K, Duong D, Di Caro V, et al.
Alzheimers Dement
. 2024 Aug;
20(10):6860-6880.
PMID: 39166791
Introduction: CT1812 is in clinical development for the treatment of Alzheimer's disease (AD). Cerebrospinal fluid (CSF) exploratory proteomics was employed to identify pharmacodynamic biomarkers of CT1812 in mild to moderate...
9.
Honig L, Sabbagh M, van Dyck C, Sperling R, Hersch S, Matta A, et al.
Alzheimers Res Ther
. 2024 Jul;
16(1):159.
PMID: 38987826
No abstract available.
10.
He J, Cabrera-Mendoza B, Friligkou E, Mecca A, van Dyck C, Pathak G, et al.
medRxiv
. 2024 Jul;
PMID: 38947007
Introduction: While higher socioeconomic factors (SEF) and cognitive performance (CP) have been associated with reduced Alzheimer's disease (AD) risk, recent evidence highlighted that these factors may have opposite effects on...